Heart failure - Classification and ESC Guideline Overview

Classification and Management of Heart Failure Introduction Heart failure is a complex clinical syndrome affecting millions of people worldwide and representing one of the most common reasons for hospital admission. Rather than a single disease, heart failure is better understood as a heterogeneous group of conditions with different underlying mechanisms, natural histories, and treatment approaches. To effectively diagnose and manage heart failure, clinicians use several classification systems that categorize the condition based on anatomical location, cardiac function, clinical timeline, and hemodynamic characteristics. This guide walks through these classification schemes and essential management principles. Classification by Affected Side Heart failure can be classified based on which side of the heart is primarily affected. Understanding this distinction is important because it affects both the clinical presentation and the management approach. Left-sided heart failure occurs when the left ventricle cannot effectively pump blood forward to the systemic circulation. Blood backs up into the pulmonary circulation, causing pulmonary congestion. This leads to symptoms like shortness of breath, particularly during exertion (dyspnea on exertion) or when lying flat (orthopnea). Right-sided heart failure develops when the right ventricle fails to pump blood forward into the pulmonary circulation. Blood backs up into the systemic venous system, causing systemic venous congestion. This presents with peripheral edema (swelling in the legs and ankles), hepatic congestion (liver enlargement), and elevated jugular venous pressure. Biventricular heart failure involves failure of both ventricles simultaneously. This often begins as left-sided failure and progresses to involve the right side as well, or may result from conditions affecting both sides. Classification by Ejection Fraction The ejection fraction (EF)—the percentage of blood ejected from the left ventricle with each contraction—is central to modern heart failure classification. Normal ejection fraction ranges from 50–75%. Heart failure is classified into three categories based on ejection fraction: Heart Failure with Reduced Ejection Fraction (HFrEF) Ejection fraction ≤ 40% HFrEF represents systolic dysfunction—the heart simply cannot generate sufficient contractile force. This is the "classic" form of heart failure most commonly caused by myocardial infarction, dilated cardiomyopathy, or chronic hypertension. HFrEF is more common in men and typically develops earlier in life. Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF) Ejection fraction 41–49% This intermediate category represents patients with borderline systolic dysfunction. Many patients progress from HFmrEF to HFrEF over time, making this a clinically important but less well-studied group. Heart Failure with Preserved Ejection Fraction (HFpEF) Ejection fraction ≥ 50% In HFpEF, systolic contraction appears normal, but the ventricle is stiff and cannot relax properly. This is called diastolic dysfunction. The ventricle cannot fill adequately during diastole despite normal contractility. HFpEF is more common in older patients, women, and those with a history of hypertension or diabetes. Managing HFpEF is challenging because it responds poorly to many of the medications that benefit HFrEF. Classification by Temporal Course Chronic Heart Failure This is a long-term condition with stable or slowly progressive symptoms. Patients maintain a compensated state with ongoing medical management. Most heart failure encountered in outpatient practice is chronic. Acute Decompensated Heart Failure This represents a rapid worsening of chronic symptoms, often triggered by infection, medication non-adherence, uncontrolled hypertension, new arrhythmias, or acute coronary syndrome. Patients may present with acute respiratory distress and require urgent hospitalization for intensive management, including intravenous diuretics and sometimes inotropic support. Classification by Cardiac Output Low-Output Heart Failure The most common form, where the heart cannot generate sufficient cardiac output despite normal or elevated filling pressures. This is what most clinicians encounter in practice. High-Output Heart Failure A less common but important category where cardiac output is actually elevated, but still insufficient to meet the body's metabolic demands. This occurs in conditions like: Severe anemia (reduced oxygen-carrying capacity drives compensatory high output) Hyperthyroidism/thyrotoxicosis (increased metabolic rate) Arteriovenous fistulas (shunting of blood bypasses tissues) Beriberi (thiamine deficiency causing vasodilation) The key distinguishing feature is that the primary problem isn't the heart's pump function but rather the body's excessive metabolic demand or peripheral vasodilation. Clinical Presentation and Diagnosis Symptoms and Physical Signs Patients with heart failure present with characteristic symptoms reflecting either pulmonary or systemic congestion: Symptoms: Dyspnea on exertion (shortness of breath with activity) Orthopnea (shortness of breath when lying flat) Paroxysmal nocturnal dyspnea (sudden awakening at night with severe breathlessness) Fatigue and exercise intolerance Peripheral edema (swelling in legs and ankles) Abdominal swelling (in right-sided failure) Physical examination findings: Elevated jugular venous pressure (visible neck vein distention) Pulmonary crackles on lung auscultation Third heart sound (S3) — a characteristic finding in systolic heart failure Displaced apical impulse (the heart's apex beat is shifted laterally) Hepatomegaly and hepatojugular reflux (in right-sided failure) Diagnostic Testing Natriuretic Peptides B-type natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) are hormones released by the heart in response to increased wall stretch. These are elevated in heart failure and serve two purposes: (1) supporting clinical diagnosis when the diagnosis is unclear, and (2) risk stratification—higher levels correlate with worse prognosis. Echocardiography This is the first-line imaging modality and should be performed in all suspected heart failure. It reveals: Ventricular size and function (allows calculation of ejection fraction) Wall motion abnormalities Valvular disease Estimated pulmonary artery pressures Diastolic function parameters Chest X-ray While not diagnostic, the chest X-ray may show signs of pulmonary congestion: Kerley B lines (horizontal lines at the lung periphery) Pulmonary edema (diffuse infiltrates) Pleural effusion Cardiomegaly (enlarged cardiac silhouette) Additional Testing Coronary angiography, cardiac MRI, or stress testing may be performed when the underlying cause is uncertain (e.g., to identify ischemic heart disease as the etiology). Special Diagnostic Algorithm for HFpEF The HFA-PEFF diagnostic algorithm integrates clinical data, natriuretic peptide levels, echocardiographic parameters (including diastolic dysfunction markers), and functional capacity assessment to confirm HFpEF diagnosis in ambiguous cases. Pharmacologic Therapy for HFrEF: The Four Pillars Treatment of HFrEF follows an evidence-based approach centered on four classes of medications that have demonstrated mortality benefit. These are typically initiated sequentially and titrated to target doses. Renin-Angiotensin System (RAS) Inhibitors This category includes: ACE Inhibitors (e.g., lisinopril, enalapril) Angiotensin II Receptor Blockers (ARBs, e.g., losartan, valsartan) Angiotensin Receptor-Neprilysin Inhibitors (ARNi, e.g., sacubitril/valsartan) These agents block the harmful effects of angiotensin II, reducing vasoconstriction, aldosterone secretion, and myocardial remodeling. RAS inhibitors reduce mortality and hospitalizations and should be initiated early in all HFrEF patients unless contraindicated. ARNi agents are increasingly preferred as they provide additional benefit through neprilysin inhibition. Beta-Blockers Agents with proven benefit include: Carvedilol Bisoprolol Metoprolol succinate (extended-release) Beta-blockers counteract the harmful effects of excessive sympathetic nervous system activation in heart failure. They improve survival and reduce hospitalizations. Note that standard immediate-release metoprolol is not recommended—only the extended-release formulation has mortality benefit. Mineralocorticoid Receptor Antagonists (MRAs) These include spironolactone and eplerenone. MRAs block aldosterone, which in heart failure causes maladaptive sodium retention, vasoconstriction, and myocardial fibrosis. These agents reduce cardiovascular mortality and should be used in all HFrEF patients with adequate renal function and normal potassium levels. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) Agents like dapagliflozin and empagliflozin were originally developed for diabetes but have now been shown to reduce heart failure hospitalizations and cardiovascular mortality in HFrEF. They are now considered part of standard therapy and may be used even in non-diabetic patients. Diuretics Loop diuretics (furosemide, bumetanide, torsemide) are essential for relieving congestion and improving symptoms, but they do not improve survival. The dose should be titrated to the minimum needed to maintain euvolemia (normal fluid balance). Patients should be monitored for electrolyte abnormalities, particularly hypokalemia and hyponatremia. Additional Agents Digoxin may be considered for symptom relief in patients with refractory congestion or for rate control in atrial fibrillation, though it has largely been replaced by newer agents. Pharmacologic Therapy for HFpEF Because HFpEF has a different underlying pathophysiology (diastolic dysfunction rather than systolic impairment), it responds differently to therapy: Hypertension Control: This is essential. ACE inhibitors, ARBs, calcium channel blockers, and diuretics all help by reducing afterload and allowing better ventricular filling. Atrial Fibrillation Management: Atrial fibrillation is common in HFpEF and significantly worsens symptoms. Both rate and rhythm control strategies with anticoagulation are important. SGLT2 Inhibitors: Recent trials have shown that SGLT2 inhibitors reduce heart failure hospitalizations in HFpEF, making them an important addition to therapy. Lifestyle Modifications: Salt restriction, fluid management, and regular exercise are keystones of HFpEF therapy. Note that many HFrEF medications (beta-blockers, ACE inhibitors, MRAs) have not consistently shown mortality benefit in HFpEF, making the therapeutic approach substantially different. Device-Based Therapies Cardiac Resynchronization Therapy (CRT) In some patients with HFrEF and left bundle branch block, the ventricles contract asynchronously, wasting cardiac output. CRT devices (biventricular pacemakers) coordinate right and left ventricular contractions, improving cardiac function. CRT improves outcomes in patients with ejection fraction ≤ 35% and QRS duration ≥ 120 ms. Implantable Cardioverter-Defibrillators (ICDs) Patients with HFrEF and ejection fraction ≤ 35% are at high risk for sudden cardiac death from ventricular fibrillation. ICDs automatically detect and terminate dangerous arrhythmias, significantly reducing sudden cardiac death. ICDs may be placed as a single device (ICD only) or combined with CRT (CRT-D). Left Ventricular Assist Devices (LVADs) For patients with advanced, refractory heart failure despite maximal medical and device therapy, LVADs provide mechanical circulatory support, serving as either a bridge to heart transplantation or as destination therapy for patients ineligible for transplant. Heart Transplantation Indicated for selected patients with end-stage heart failure refractory to all medical and device therapies who have acceptable transplant risk and good functional status. Management of Specific Heart Failure Types Acute Right-Heart Failure This requires aggressive preload reduction (cautious diuretics), pulmonary vasodilators (inhaled nitric oxide, inhaled epoprostenol), and treatment of the underlying cause (usually pulmonary hypertension). High-Output Heart Failure Treatment focuses on addressing the underlying cause: controlling thyroid hormone excess in thyrotoxicosis, transfusing severe anemia, closing arteriovenous fistulas, or supplementing thiamine in beriberi. Iron Deficiency Anemia Iron deficiency worsens heart failure symptoms and functional capacity. Intravenous iron supplementation improves outcomes and is recommended for heart failure patients with iron deficiency. Hyponatremia Severe hyponatremia (low serum sodium) indicates neurohormonal activation and carries prognostic significance. Management includes free water restriction, optimization of diuretic therapy, and in severe cases, vasopressin antagonists. <extrainfo> Lifestyle and Non-Pharmacologic Management These interventions support medical therapy and prevent decompensation: Sodium restriction: < 2 g per day (approximately 5 g of salt) Fluid restriction: ≤ 1.5 L per day in severe congestion or hyponatremia Regular aerobic exercise: Improves functional capacity and quality of life; supervised cardiac rehabilitation is beneficial Smoking cessation and alcohol moderation: Reduce cardiovascular risk Patient education: Self-monitoring of weight and symptoms with rapid response to changes decreases readmission rates </extrainfo> <extrainfo> Monitoring and Follow-up Daily weight monitoring: Detects early fluid accumulation (typical threshold: alert if > 2–3 lbs gained in 1 day or > 5 lbs in 1 week) Structured telephone support or telemonitoring: Reduces hospitalizations Remote monitoring devices: Some ICDs and pacemakers can monitor intrathoracic impedance, heart rate, and rhythm to provide early warning of decompensation Biomarker testing: Serial BNP/NT-proBNP measurements guide therapy adjustments Follow-up assessments: Regular visits evaluate symptoms, functional status, medication tolerance, and laboratory parameters (renal function, electrolytes, potassium) </extrainfo> <extrainfo> Prognosis and Palliative Considerations Prognostic markers indicating worse outcomes include: Elevated natriuretic peptides Reduced ejection fraction Renal dysfunction (elevated creatinine) Frequent hospitalizations New York Heart Association functional class III–IV With modern therapies, many patients achieve significant symptom improvement and stabilization. However, advanced heart failure carries substantial morbidity and mortality, making discussion of goals of care, advance directives, and palliative care services important for quality of life. </extrainfo>